Philippe Hernigou1, Charlie Bouthors2, Claire Bastard3, Charles Henri Flouzat Lachaniette3, Helene Rouard4, Arnaud Dubory3. 1. Orthopedic Department Henri Mondor Hospital, University Paris East, Creteil, France. philippe.hernigou@wanadoo.fr. 2. Orthopedic Department Kremlin Bicêtre Hospital, University Paris Sud, Kremlin Bicetre, France. 3. Orthopedic Department Henri Mondor Hospital, University Paris East, Creteil, France. 4. Cellular Therapy, Henri Mondor Hospital, University Paris East, Creteil, France.
Abstract
PURPOSE: There is an increasing number of reports on the treatment of knee osteoarthritis (OA) using mesenchymal stem cells (MSCs). However, it is not known what would better drive osteoarthritis stabilization to postpone total knee arthroplasty (TKA): targeting the synovial fluid by injection or targeting on the subchondral bone with MSCs implantation. METHODS: A prospective randomized controlled clinical trial was carried out between 2000 and 2005 in 120 knees of 60 patients with painful bilateral knee osteoarthritis with a similar osteoarthritis grade. During the same anaesthesia, a bone marrow concentrate of 40 mL containing an average 5727 MSCs/mL (range 2740 to 7540) was divided in two equal parts: after randomization, one part (20 mL) was delivered to the subchondral bone of femur and tibia of one knee (subchondral group) and the other part was injected in the joint for the contralateral knee (intra-articular group). MSCs were counted as CFU-F (colony fibroblastic unit forming). Clinical outcomes of the patient (Knee Society score) were obtained along with radiological imaging outcomes (including MRIs) at two year follow-up. Subsequent revision surgeries were identified until the most recent follow-up (average of 15 years, range 13 to 18 years). RESULTS: At two year follow-up, clinical and imaging (MRI) improvement was higher on the side that received cells in the subchondral bone. At the most recent follow-up (15 years), among the 60 knees treated with subchondral cell therapy, the yearly arthroplasty incidence was 1.3% per knee-year; for the 60 knees with intra-articular cell therapy, the yearly arthroplasty incidence was higher (p = 0.01) with an incidence of 4.6% per knee-year. For the side with subchondral cell therapy, 12 (20%) of 60 knees underwent TKA, while 42 (70%) of 60 knees underwent TKA on the side with intra-articular cell therapy. Among the 18 patients who had no subsequent surgery on both sides, all preferred the knee with subchondral cell therapy. CONCLUSIONS: Implantation of MSCs in the subchondral bone of an osteoarthritic knee is more effective to postpone TKA than injection of the same intra-articular dose in the contralateral knee with the same grade of osteoarthritis.
RCT Entities:
PURPOSE: There is an increasing number of reports on the treatment of knee osteoarthritis (OA) using mesenchymal stem cells (MSCs). However, it is not known what would better drive osteoarthritis stabilization to postpone total knee arthroplasty (TKA): targeting the synovial fluid by injection or targeting on the subchondral bone with MSCs implantation. METHODS: A prospective randomized controlled clinical trial was carried out between 2000 and 2005 in 120 knees of 60 patients with painful bilateral knee osteoarthritis with a similar osteoarthritis grade. During the same anaesthesia, a bone marrow concentrate of 40 mL containing an average 5727 MSCs/mL (range 2740 to 7540) was divided in two equal parts: after randomization, one part (20 mL) was delivered to the subchondral bone of femur and tibia of one knee (subchondral group) and the other part was injected in the joint for the contralateral knee (intra-articular group). MSCs were counted as CFU-F (colony fibroblastic unit forming). Clinical outcomes of the patient (Knee Society score) were obtained along with radiological imaging outcomes (including MRIs) at two year follow-up. Subsequent revision surgeries were identified until the most recent follow-up (average of 15 years, range 13 to 18 years). RESULTS: At two year follow-up, clinical and imaging (MRI) improvement was higher on the side that received cells in the subchondral bone. At the most recent follow-up (15 years), among the 60 knees treated with subchondral cell therapy, the yearly arthroplasty incidence was 1.3% per knee-year; for the 60 knees with intra-articular cell therapy, the yearly arthroplasty incidence was higher (p = 0.01) with an incidence of 4.6% per knee-year. For the side with subchondral cell therapy, 12 (20%) of 60 knees underwent TKA, while 42 (70%) of 60 knees underwent TKA on the side with intra-articular cell therapy. Among the 18 patients who had no subsequent surgery on both sides, all preferred the knee with subchondral cell therapy. CONCLUSIONS: Implantation of MSCs in the subchondral bone of an osteoarthritic knee is more effective to postpone TKA than injection of the same intra-articular dose in the contralateral knee with the same grade of osteoarthritis.
Authors: Giles R Scuderi; Alla Sikorskii; Robert B Bourne; Jess H Lonner; James B Benjamin; Philip C Noble Journal: Clin Orthop Relat Res Date: 2016-01 Impact factor: 4.176
Authors: Danielle Y Ponzio; Yu-Fen Chiu; Anthony Salvatore; Yuo-Yu Lee; Stephen Lyman; Russell E Windsor Journal: J Bone Joint Surg Am Date: 2018-09-19 Impact factor: 5.284
Authors: B P Katz; D A Freund; D A Heck; R S Dittus; J E Paul; J Wright; P Coyte; E Holleman; G Hawker Journal: Health Serv Res Date: 1996-06 Impact factor: 3.402
Authors: Benjamin M Davies; Sarah J B Snelling; Lynn Quek; Osnat Hakimi; Hua Ye; Andrew Carr; Andrew J Price Journal: J Orthop Res Date: 2017-03-02 Impact factor: 3.494
Authors: Ria Margiana; Alexander Markov; Angelina O Zekiy; Mohammed Ubaid Hamza; Khalid A Al-Dabbagh; Sura Hasan Al-Zubaidi; Noora M Hameed; Irshad Ahmad; R Sivaraman; Hamzah H Kzar; Moaed E Al-Gazally; Yasser Fakri Mustafa; Homayoon Siahmansouri Journal: Stem Cell Res Ther Date: 2022-07-28 Impact factor: 8.079
Authors: Christoph Schmitz; Christopher Alt; David A Pearce; John P Furia; Nicola Maffulli; Eckhard U Alt Journal: Cells Date: 2022-03-11 Impact factor: 6.600